over 2 years ago • 1 min
Crispr Therapeutics shares fell after the biotech firm gave an update late Tuesday on its CAR-T cancer therapy that disappointed investors.
The stock dropped as much as 6% to $96.01 in pre-market trading on Wednesday, the lowest since November. Crispr said a study showed the therapy cleared cancer cells in nine patients in a 24-person study.
Crispr is Ark Investment Management’s 18th biggest holding across its six actively managed funds. The investment firm founded by Cathie Wood is Crispr’s biggest shareholder, with a 10% stake.
Ark’s Genomic Revolution exchange-traded fund (ticker: ARKG) and its flagship Ark Innovation ETF (ticker: ARKK) each bought extra shares in Crispr this week, before Tuesday’s announcement. The stock’s decline creates another headache for the two funds, which are down more than 10% so far in 2021.
Wall Street analysts are still fairly bullish on Crispr shares, for now: as the chart shows, the stock is trading near a record discount to their average price target. Fifteen of 22 analysts tracked by Bloomberg rate the company a “buy” and on aggregate they see the stock gaining 67% over the next year. Let’s see if Tuesday’s update prompts any of them to lower their projections.
Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.